Spleen selective enhancement of transfection activities of plasmid DNA driven by octaarginine and an ionizable lipid and its implications for cancer immunization.
Animals
B-Lymphocytes
/ metabolism
DNA
/ metabolism
Female
Gene Transfer Techniques
Humans
Hydrogen-Ion Concentration
Immunization
Lipids
/ chemistry
Liver
/ metabolism
Male
Mice, Inbred C57BL
Mice, Inbred ICR
Nanocapsules
/ chemistry
Neoplasms
/ therapy
Oligopeptides
/ chemistry
Piperidines
/ chemistry
Plasmids
/ chemistry
Spleen
/ metabolism
Transfection
Gene delivery
R8
Spleen
YSK05
pDNA
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
10 11 2019
10 11 2019
Historique:
received:
18
04
2019
revised:
13
08
2019
accepted:
14
09
2019
pubmed:
19
9
2019
medline:
9
10
2020
entrez:
19
9
2019
Statut:
ppublish
Résumé
Efficiently delivering plasmid DNA (pDNA) to the spleen is particularly significant for DNA immunization. However, increasing the efficiency of gene expression in spleen cells for achieving a therapeutic effect remains a serious challenge. An ideal spleen-targeted system should avoid liver uptake and should efficiently transfect specific functional spleen cells. Here, we report on pDNA nanocarriers with enhanced transfection in spleen cells driven by synergism between an octaarginine (R8) peptide and YSK05; a pH-responsive ionizable lipid. A double-coating design is essential for enhancing spleen selective transfection which is significantly affected by the total amount of lipid and the composition of the outer coat. The optimized R8/YSK system shows a high gene expression in the spleen with a high spleen/liver ratio and a surprising ability to target spleen B cells. Compared to other organs, the high spleen activity cannot be explained based on the amount of pDNA delivered to each organ, indicating that the system is extremely efficient in transfecting spleen cells. The system can be used in cancer immunization where a strong anti-tumor effect was observed in mice immunized with the R8/YSK system encapsulating antigen-encoding pDNA. The R8/YSK system holds great promise for future applications in the field of DNA vaccination.
Identifiants
pubmed: 31526828
pii: S0168-3659(19)30550-4
doi: 10.1016/j.jconrel.2019.09.009
pii:
doi:
Substances chimiques
Lipids
0
Nanocapsules
0
Oligopeptides
0
Piperidines
0
YSK05
0
octaarginine
0
DNA
9007-49-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
70-79Informations de copyright
Copyright © 2019. Published by Elsevier B.V.